OTCMKTS:CXRXF ADVANZ PHARMA (CXRXF) Stock Price, News & Analysis $17.06 0.00 (0.00%) As of 06/10/2021 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About ADVANZ PHARMA Stock (OTCMKTS:CXRXF) Get ADVANZ PHARMA alerts:Sign Up Key Stats Today's Range$17.06▼$17.0650-Day Range$17.06▼$17.0652-Week Range$2.13▼$18.00Volume39 shsAverage Volume11,851 shsMarket Capitalization$834.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Advanz Pharma is a specialty pharmaceutical company focused on the development, acquisition and commercialization of off-patent and niche branded medicines. The firm seeks to address gaps in treatment by bringing a diverse portfolio of established pharmaceuticals to market, often targeting therapeutic areas such as endocrinology, oncology and pain management. Advanz Pharma’s strategy combines lifecycle management of legacy brands with selective investment in product improvements and regulatory filings to extend market exclusivity and patient access. The company’s product range includes hormonal therapies for endocrine disorders, pain management medicines including branded analgesics, and supportive care products used alongside oncology treatments. Advanz Pharma leverages its regulatory expertise to maintain uninterrupted supply of medicines that have limited competition, and it actively pursues approvals and registrations in multiple jurisdictions. Its commercial model emphasizes partnerships with local distributors and direct sales teams to maximize market penetration in each territory. Advanz Pharma was established in 2018 following a carve-out of certain pharmaceutical assets from a larger specialty pharma group. Since then, it has built a presence across Europe and Canada, with key markets including the United Kingdom, Germany, Italy and select Nordic countries. Headquartered in London, the company operates regional offices and collaborates with healthcare providers to support product uptake and patient education. Through its focused portfolio and agile launch capabilities, Advanz Pharma aims to sustain growth by addressing unmet needs in niche therapeutic segments.AI Generated. May Contain Errors. Read More Receive CXRXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADVANZ PHARMA and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CXRXF Stock News HeadlinesPHAT Phathom Pharmaceuticals, Inc.April 6, 2024 | seekingalpha.comDimerix completes ‘highly strategic’ $20m cap raise to advance ACTION3 Phase 3 trialMarch 12, 2024 | msn.comPass by August 7… or wait until 2027?Wall Street doesn't move on hype. It moves on infrastructure. And as the CLARITY Act works through Washington, banks and asset managers may soon have a clearer path to move serious capital onto blockchain rails. We believe one under-$1 token was built for exactly that moment. This network was designed for regulated finance… including tokenized securities, institutional settlement, stablecoin payments, privacy and compliance. Its ecosystem already includes major financial names such as Goldman Sachs, J.P. Morgan, Bank of America and Citadel.August 4 at 1:00 AM | Crypto 101 Media (Ad)Interim results for Dimerix’s Phase 3 trial of DXB-200 for FSGS kidney disease on track for release in March 2024February 27, 2024 | msn.comDimerix receives $10.7 million upfront payment from Advanz PharmaNovember 7, 2023 | msn.comApplied Therapeutics adds 19% on partnership with Advanz Pharma for lead assetJanuary 4, 2023 | msn.comMADE in America Act is critical for the pharmaceutical industrySeptember 27, 2022 | dallasnews.comDPolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in EuropeAugust 5, 2022 | seekingalpha.comSee More Headlines CXRXF Stock Analysis - Frequently Asked Questions How have CXRXF shares performed this year? ADVANZ PHARMA's stock was trading at $17.06 on January 1st, 2026. Since then, CXRXF shares have increased by 0.0% and is now trading at $17.06. How do I buy shares of ADVANZ PHARMA? Shares of CXRXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:CXRXF CIKN/A Webwww.advanzpharma.com Phone44-20-8588-9100FaxN/AEmployees429Year Founded2006Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$74.86 million Net Margins-15.31% Pretax MarginN/A Return on EquityN/A Return on Assets-4.38% Debt Debt-to-Equity Ratio257.04 Current Ratio2.39 Quick Ratio1.61 Sales & Book Value Annual Sales$525.58 million Price / Sales1.59 Cash FlowN/A Price / Cash FlowN/A Book Value$0.16 per share Price / Book106.63Miscellaneous Outstanding Shares48,913,000Free FloatN/AMarket Cap$834.46 million OptionableNot Optionable BetaN/A Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (OTCMKTS:CXRXF) was last updated on 8/4/2026 by MarketBeat.com Staff. From Our Partners"Second Wave” Hitting Iran Soon? Wall Street Issues WarningAnalysts at Goldman Sachs and Morgan Stanley are warning that a quiet domestic threat - unrelated to overseas ...TradeSmith | Sponsored1 Stock to Own by July 31stA scheduled announcement on July 31st could reshuffle the stock market's winners and losers - and one lesser-k...Chaikin Analytics | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredThis AI fund sends investors payouts every ThursdayCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredHe bet half his $9 billion on ONE stockOne of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund ...Stansberry Research | SponsoredThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADVANZ PHARMA Corp. Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share ADVANZ PHARMA With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.